Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Patients with hematologic malignancies frequently become thrombocytopenic as a result of their underlying malignancy or treatments, including cytotoxic chemotherapy and hematopoietic stem cell transplantation and are at increased risk of hemorrhage. Prophylactic platelet transfusions are aimed at preventing severe or life-threatening hemorrhage. This review summarizes recent evidence, including the need for prophylactic platelet transfusions, the optimal dose, platelet transfusion triggers, and risk factors for bleeding. It also discusses controversies surrounding platelet transfusions in this population.

Original publication




Journal article


Hematol Oncol Clin North Am

Publication Date





541 - 560


Acute leukemia, Bleeding, Chemotherapy, Hematopoietic stem cell transplantation, Platelet transfusion, Thrombocytopenia, Allografts, Clinical Trials as Topic, Hematopoietic Stem Cell Transplantation, Hemorrhage, Humans, Neoplasms, Platelet Transfusion, Risk Factors, Thrombocytopenia